Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.

Sternschuss, Michal; Yerushalmi, Rinat; Saleh, Ramy R; Amir, Eitan; Goldvaser, Hadar

Sternschuss, Michal; Yerushalmi, Rinat; Saleh, Ramy R; Amir, Eitan; Goldvaser, Hadar.

Affiliation

Sternschuss M; Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 39 Jabotinski St., 49100, Petah Tikva, Israel.
Yerushalmi R; Sackler Faculty of Medicine, Tel Aviv University, PO Box 39040, 6997801, Tel Aviv, Israel.
Saleh RR; Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 39 Jabotinski St., 49100, Petah Tikva, Israel.
Amir E; Sackler Faculty of Medicine, Tel Aviv University, PO Box 39040, 6997801, Tel Aviv, Israel.
Goldvaser H; Cedars Cancer Center, McGill University Health Center, 1001 Decarie Blvd, Montreal, QC, H4A 3J1, Canada.

J Cancer Res Clin Oncol ; 147(11): 3369-3379, 2021 Nov.

Article de En | MEDLINE | ID: mdl-33745080

Sujet(s)
Mots clés

Immune checkpoint inhibitors; Immunotherapy; Neoadjuvant; Pathological complete response; Triple-negative breast cancer

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Tumeurs du sein triple-négatives Type d'étude: Clinical_trials / Systematic_reviews Limites: Humans Langue: En Journal: J Cancer Res Clin Oncol Année: 2021 Type de document: Article Pays d'affiliation: Israël Pays de publication: Allemagne

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google